Opinion|Videos|February 27, 2026
US Real World CAR-T Patterns in R/R LBCL (ASH 2025 Updates from ABC Consortium)
Panelists discuss real-world data from the US ABC Consortium evaluating axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in relapsed/refractory LBCL. Faculty discuss key differences in manufacturing, review outcomes, and consider toxicity profiles for each of the CAR T products in clinical practice.
Advertisement
Episodes in this series
Panelists discuss real-world data from the US ABC Consortium evaluating axicabtageneciloleucel, tisagenlecleucel, and lisocabtagenemaraleucel in relapsed/refractory LBCL. Faculty discuss key differences in manufacturing, review outcomes, and consider toxicity profiles for each of the CAR T products in clinical practice.
Advertisement
Related to this article
Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.
Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
4
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
5